TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06192693
Drug: Capsulized placebo transfer containing dilution solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Placebo of FMT=30 capsulized given during 2 days in several intakes per day (3 intakes per day).~Placebo of FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion \>8%.
Study: NCT06005493
Drug: AZD5863
Approvals — FDA: no, EMA: no, PMDA: no
Description: T cell-engaging bi-specific antibody that targets CLDN18.2 (Claudin18.2) on tumor cells and CD3 on T cells
Study: NCT05527418
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during 16 weeks.
Study: NCT06557161
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
Study: NCT06499324
Drug: BTA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: It consists of a blind injection of 288 IU (/144mL) of BTA (XEOMIN®) into the lateral muscles (18 injection sites, 16UI/8mL/injection site), 4 to 6 weeks before the treatment of a large anterior IH (width ≥ 10 cm) with open non absorbable mesh repair. The injection of BTA (XEOMIN®) will be done during an outpatient hospitalization, in each of the 3 lateral muscles of the abdomen on each side. To do this in the BTA group, 3 vials of 100 equivalent IU of BTA (XEOMIN® 100U), diluted to 2 IU/mL with 0.9% saline will be distributed in 3 syringes of 50 mL equipped with a 21G needle. A total of 72 mL of BTA solution (144 IU) will be injected on each side, at 3 injection points between the costal rim and iliac crest, under ultrasound control.
Study: NCT06499324
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: It consists of a blind injection of placebo of BTA (XEOMIN® 100U matching placebo) into the lateral muscles (18 injection sites, 8mL/injection site), 4 to 6 weeks before the treatment of a large IH (width \>= 10 cm) with open non absorbable mesh repair. The injection of placebo of BTA (XEOMIN® 100U matching placebo) will be done during an outpatient hospitalization, in each of the 3 lateral muscles of the abdomen on each side. To do this in the control group, 3 vials of placebo of BTA (XEOMIN® 100U matching placebo), diluted with 0.9% saline will be distributed in 3 syringes of 50 mL equipped with a 21G needle. A total of 72 mL of placebo of BTA solution will be injected on each side, at 3 injection points between the costal rim and iliac crest, under ultrasound control.
Study: NCT06362759
Drug: TOUR006 - 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOUR006 15 MG
Study: NCT05307328
Drug: SPI-62
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor
Study: NCT05307328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive tablets identical to SPI-62 tablets
Study: NCT05367245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only Cal-Mag but no Butyric acid
Study: NCT05971940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05485961
Drug: CSL300
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration
Study: NCT05485961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% w/v NaCl
Study: NCT05485961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching the excipient content and concentration of the CSL300 product, minus the active ingredient.
Study: NCT05731947
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either Lonsurf® or Stivarga® administered per the investigator's choice at the respective drug label's dose and schedule. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
Study: NCT06685445
Drug: Active Comparator: Continue Erector Spinae Plane Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the block, the ultrasound (USG)probe will be placed longitudinally 2-3 cm lateral to the transverse process of the T4-5 vertebra. The erector spinae muscle will be visualized above the hyperechoic transverse process. Using in plane technique, the block needle will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the erector spinae muscle to confirm the block site. After the block site is confirmed, 30 ml of 0.25% bupivacaine (Marcain 0.5%® AstraZeneca, England) will be administered. The block catheter (Perifix® Braun, Germany) will then be inserted to block area
Study: NCT06685445
Drug: Active Comparator: Continue Erector Spinae Plane Block + Serratus Anterior Plane Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: For ESPB, USG probe will be placed longitudinally 2-3 cm lateral to the transverse process of the T4-5 vertebra. The erector spinae muscle will be visualized above the hyperechoic transverse process. Using in plane technique, the block needle will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the erector spinae muscle to confirm the block site and 30 ml of 0.25% bupivacaine (Marcain®) will be administered. The block catheter (Perifix®) will be inserted. For SAPB, the USG probe will be placed parasagittal to the mid-axillary line at the 5th-6th rib level and the anechoic shadow of the costa together with the latissumus dorsi and serratus anterior muscles will be visualized. Then using in plane technique, the block needle will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the serratus anterior muscle and the block site will be confirmed and 30 ml of 0.25% bupivacaine will be administered.
Study: NCT05945420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This arm will receive tamsulosin and placebo
Study: NCT06559345
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
Study: NCT05712174
Drug: [18]F-PSMA-1007
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18\]F-PSMA-1007 is a diagnostic radiopharmaceutical for use with PET/CT or PET/MRI scanning to diagnose prostate cancer.
Study: NCT06102005
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study: NCT06785116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take this daily for 6-months. Additionally, during the study participants will have 4 study visits and be asked to complete study specific activities (i.e. daily blood pressure, weekly weights, laboratory draws, echocardiograms, etc.) Participants will be followed remotely for 1-month after the 6-month visit.
Study: NCT04932395
Drug: Anshen Buxin Liuwei Pill
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 capsules/time, 2 times/day, orally.
Study: NCT04932395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo simulated as the Anshen Buxin Liuwei Pills with same appearance，smell and taste,15 capsules/time, 2 times/day, orally.
Study: NCT05248776
Drug: CPL207280
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
Study: NCT05248776
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet.
Study: NCT06782685
Drug: LV
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg/m\^2, i.v.，d1
Study: NCT06785454
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorundrostat matching placebo tablet.
Study: NCT06772415
Drug: GenSci122 tablet 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally Once Daily
Study: NCT06772415
Drug: GenSci122 tablet 250mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally Once Daily
Study: NCT06778759
Drug: Ibuprofen Arginine
Normalized name: ibuprofen arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen arginine oral tablets
Study: NCT04864522
Drug: SLAMF7 FPBMC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 8 weekly infusions of SLAMF7 FPBMC, then 8 additional infusions every 2 weeks.
Study: NCT05408910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this arm will receive placebo three times daily for 14 days.
Study: NCT05399485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization Phase: Placebo tablet to match Rimegepant every other day until Week 12
Study: NCT05027945
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For 7/8 Matched Related or Unrelated or Haploidentical Donor, prior to transplant 14.5 mg/kg IV daily on days -6 and -5
Study: NCT04868877
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: administrated by IV infusion
Study: NCT05873062
Drug: AUT00201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT05873062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT05282550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 4 weeks.
Study: NCT05016882
Drug: NNC0194 0499 50 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive subcutaneous (s.c., under the skin) injections of NNC0194-0499 once weekly The study will last for about 19 months
Study: NCT05016882
Drug: Placebo (NNC0194-0499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive subcutaneous (s.c., under the skin) injections of placebo once weekly The study will last for about 19 months
Study: NCT05016882
Drug: NNC0174 0833 10 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 once weekly The study will last for about 19 months
Study: NCT05016882
Drug: NNC0174 0833 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 placebo once weekly The study will last for about 19 months
Study: NCT04948489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule everyday for 12 months
Study: NCT04167969
Drug: (64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be injected with approximately 5 mCi (+/- 10%) of a copper-64 (64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots, up to 48 hours before surgery.
Study: NCT06579300
Drug: Placebo for ABBV-1088
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT05583773
Drug: ShengXian-QuYu Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specification: 30ml/bag, given twice daily, per oral use.
Study: NCT04582383
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dispensation of spironolactone according to the arm description.
Study: NCT05039177
Drug: ERAS-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05661942
Drug: Calcium pre-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention is Calcium gluconate 1 gram/100ml 0.9% NaCl or 100ml 0.9% NaCl) over 5 minutes.
Study: NCT05799287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Telitacicept
Study: NCT05457972
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imvexxy is an FDA-approved drug produced by TherapeuticsMD.
Study: NCT04695197
Drug: Artemether-lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current first line treatment of malaria. Dose: Bodyweight (kg) Dose (mg) of artemether + lumefantrine given twice daily for 3 days (total, six doses) 5 to \< 15 20 + 120 15 to \< 25 40 + 240 25 to \< 35 60 + 360 \>=35 80 + 480; Twice daily for 3 days (total, six doses)
Study: NCT05826912
Drug: Minocycline Hydrochloride
Normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule, 200 mg loading dose on Day 1, then 100 mg twice daily for 6 days, then placebo twice daily for 21 days
Study: NCT05826912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, 2x/day for 28 days
Study: NCT06775327
Drug: INCB000631
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral; Tablet
Study: NCT06775327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral; Tablet
Study: NCT06775340
Drug: RSS0343 Tabella
Normalized name: ZINC OXIDE 29.4 mg in 1 mL / OCTINOXATE 29.4 mg in 1 mL TOPICAL LOTION [Abella ColorShade SPF 35 Medium]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSS0343 tablets, oral;
Study: NCT05459142
Drug: Medical Abortion
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Abortion
Study: NCT04922021
Drug: LEO 138559
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LEO 138559 is an antibody given by injection just under the skin.
Study: NCT04922021
Drug: LEO 138559 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except for the medical ingredient LEO 138559.
Study: NCT05645393
Drug: topical estrogen product
Normalized name: Estrogel Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: estrogen topical gel or cream
Study: NCT06779851
Drug: BPT567
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunocytokine infusion
Study: NCT06780202
Drug: medrol dosepak
Normalized name: Medrol Dosepak
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone is a corticosteroid with anti-inflammatory properties and immune suppression.~This study will utilize a 6-day Medrol Dosepak: a tapered low-dose corticosteroid course taken orally once a day. This includes 6 tablets on day 1 (24 mg), 5 tablets on day 2 (20 mg), 4 tablets on day 3 (16 mg), 3 tablets on day 4 (12 mg), 2 tablets on day 5 (8 mg) and 1 tablet on day 6 (4 mg).
Study: NCT06780202
Drug: HYDROcodone Oral Tablet
Normalized name: hydrocodone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study will utilize a prescription of 20 pills of hydrocodone, 5mg each, to be taken as needed for pain, 1 every 6 hours.
Study: NCT06781489
Drug: Ibuprofen Arginine
Normalized name: ibuprofen arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen arginine tablets
Study: NCT05292664
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lumbar Puncture
Study: NCT05292664
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lumbar Puncture
Study: NCT05292664
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taken Orally or intravenously
Study: NCT05292664
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taken intravenously
Study: NCT06781983
Drug: IPH4502
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 (dose escalation) and Part 2 (dose optimization)
Study: NCT06785272
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: After initial therapy with the systemic CSs routinely used for acute asthma management at a given site, 3 treatments with inhaled salbutamol and ipratropium, eligible patients with PRAM ≥5 will, under the care of the research nurse, receive a 30-minute IV infusion of 0.9% saline \[control group\].
Study: NCT05843578
Drug: AGMB-129
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT05843578
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral capsule
Study: NCT05234762
Drug: ES-481
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation during two Treatment Periods
Study: NCT05748366
Drug: Standard Analgesic Medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic medications will be administered via the intravenous, intramuscular or oral route at the discretion of the medical treatment team.
Study: NCT05543603
Drug: Lacer Clorhexidine 0.20% Colutorio
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml 0,2% Chlorhexidine, one minute rinse
Study: NCT05543603
Drug: Gingilacer Encías Delicadas Colutorio
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml 0,10% cymenol + 0,10% zinc chloride, one minute rinse
Study: NCT05488873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo Topical Solution
Study: NCT06703177
Drug: Fluorouracil Injection
Normalized name: fluorouracil Injection
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil Injection
Study: NCT06204432
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Those randomized to the Normal Saline arm will use 1 mL of normal saline, 0.5 mL in each nostril, twice a day via an atomizer followed by olfactory training.
Study: NCT05741229
Drug: conventional therapy for PPHN
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive sildenafil which is used routinely in management of PPHN in our unit, in addition to appropriate oxygenation and ventilation.
Study: NCT06299098
Drug: Matching Placebo-Part A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV or SC in Part A
Study: NCT06550362
Drug: iron sulfate
Normalized name: iron sulfate (1:1)
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral iron administration
Study: NCT05902533
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m2 BID (Oral Twice daily on days with RT)
Study: NCT04932915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo formulation contains purified water, sodium chloride as common isotonizing agent and the FAO/WHO approved colorant FD\&C Red 40 to match the red-orange colour of the active solution. The solution is administered directly to the nasal cavity via a nasal spray.
Study: NCT05465941
Drug: Pegylated SN-38 Conjugate PLX038
Normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05461352
Drug: TS-142 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received repeated doses of 5 mg of TS-142 (oral tablet)
Study: NCT05461352
Drug: TS-142 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received repeated doses of 10 mg of TS-142 (oral tablet)
Study: NCT05198934
Drug: Trifluridine and Tipiracil
Normalized name: tipiracil / trifluridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine and Tipiracil will be administered orally
Study: NCT05673200
Drug: Decitabine and Cedazuridine
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06534125
Drug: Aromatase Inhibition Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive SOC AI therapy
Study: NCT04913272
Drug: US-APR2020
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-APR2020 capsules 45 billion CFUs of the LBT.
Study: NCT04913272
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06577181
Drug: hCG + estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human chorionic gonadotropins
Study: NCT05968430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, administered orally
Study: NCT06440525
Drug: RSLV-132
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fc fusion protein comprised of catalytically active human ribonuclease (RNase) fused to human immunoglobulin G1 (IgG1)
Study: NCT06440525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride solution
Study: NCT06379789
Drug: REGV131
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administered via intravenous (IV) infusion before LNP1265
Study: NCT06379789
Drug: LNP1265
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administered via IV infusion following REGV131
Study: NCT05228574
Drug: Amiloride Hcl 5mg Tab
Normalized name: AMILORIDE HCL 5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 5mg tablets, 20 mg per day for two weeks in open-label setting.
Study: NCT06331559
Drug: SIM0501 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every 28 days is one cycle. Multiple dose levels of SIM0501 will be explored in dose escalation, and determine the maximum tolerated dose.
Study: NCT06331559
Drug: SIM0501 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0501 established from SIM0501 mono dose escalation.
Study: NCT05979857
Drug: SP-3164
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP-3164, an oral next generation cereblon-binding molecular glue 'protein degrader'
Study: NCT05874700
Drug: Placebo was given intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia induction began with a 0.2mg/Kg/h pump test drug until 48 hours after endotracheal intubation was removed or up to 7 days. If the patient was judged to have successfully removed the endotracheal tube, drug administration was discontinued; If the endotracheal intubation was not removed successfully up to 7 days, drug administration was also discontinued. During CPB, 0.1mg/100mL of the experimental drug was injected into the circulating pump immediately after CPB began.
Study: NCT05928936
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants take placebo pills to match 650-1300 mg of sodium bicarbonate orally twice daily.
Study: NCT05411016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered single dose or multiple dose by IV or SC injection